The development of immunotherapy agents has revolutionized the field of oncology. The
only FDA-approved immunotherapeutic approach in breast cancer consists of immune …

Simple Summary For decades, countless efforts have been devoted to developing targeted
drugs to improve the prognosis of triple-negative breast cancer (TNBC). Among the novel …

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of
breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the …

Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …

Abstract Triple Negative Breast Cancer (TNBC) is a highly heterogeneous subtype of breast
cancer that lacks the expression of oestrogen receptors, progesterone receptors and human …

Patients with breast tumors that do not express the estrogen receptor, the progesterone
receptor, nor Her-2/neu are hence termed “triple negatives”, and generally have a poor …

Highlights•TNBCs is one of the most heterogenous form of breast cancer appear to have
elevated numbers of immune cells infiltration.•Using immune checkpoint inhibitors (ICIs) …

Triple-negative breast cancer (TNBC), a subtype of breast cancer, is defined as lacking
estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor …

Introduction Triple negative breast cancer (TNBC) is an area of high unmet medical need in
terms of new effective treatment strategies. Although breast cancer is traditionally …

Purpose Immunotherapy has started to transform the treatment of triple-negative breast
cancer (TNBC), in part due to the unique immunogenicity of this breast cancer subtype. This …